Seer

Seer is a commercial-stage proteomics company aiming to accelerate the field of proteomics to match the pace of genomics. Its core innovation is the Proteograph Product Suite, a nanoparticle-based enrichment technology that enables deep, unbiased, and scalable proteomic analysis from complex biological samples. The company's strategy involves selling its integrated platform (assays, consumables, software) while also offering high-value service contracts through its Seer Technology Access Center (STAC) to drive adoption and generate revenue. Despite a challenging market valuation, Seer has established a growing catalog of definitively identified proteins and is focused on penetrating academic, biopharma, and clinical research markets.

Proprietary nanoparticle-based protein enrichment technology (Proteograph) that enables unbiased, deep, and scalable proteomic analysis from complex biological samples, coupled with integrated data analysis software.

Seer competes with targeted, high-throughput proteomic platforms (e.g., Olink, Somalogic) and traditional mass spectrometry sample prep methods. Its differentiation is unbiased discovery and depth at scale, bolstered by a recently upheld patent on its nanoparticle enrichment technology.